SC
TVRD

Shay Capital’s Tvardi Therapeutics TVRD Stock Holding History

Shay Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,564
Closed -$524K – 435
2024
Q4 		$524K Buy
+28,564
New +$311K 0.08% 175
2023
Q3 		– Sell
-347
Closed -$35.4K – 519
2023
Q2 		$35.4K Buy
+347
New +$47.8K ﹤0.01% 368

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Shay Capital's TVRD Position: Q1 2025 in Review

Shay Capital sold out of Tvardi Therapeutics (TVRD) in Q1 2025, closing a stake of 28,564 shares — an estimated $524K sold.

Shay Capital first reported a position in TVRD in Q2 2023 and held it in 2 quarters. The position peaked at $524K in Q4 2024. 33 funds tracked by Wall St. Rank hold TVRD as of Q1 2025.

  • Shay Capital reported no remaining Tvardi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Shay Capital sold 28,564 Tvardi Therapeutics shares in Q1 2025, an estimated $524K.
  • Shay Capital first reported a position in Tvardi Therapeutics in Q2 2023 and held it in 2 quarters.
  • Shay Capital's Tvardi Therapeutics position peaked at $524K in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2025.

Based on Shay Capital's 13F filing for Q1 2025, filed 15 May 2025.